EA201792012A1 - Использование щелочных промывочных растворов во время хроматографии для удаления примесей - Google Patents

Использование щелочных промывочных растворов во время хроматографии для удаления примесей

Info

Publication number
EA201792012A1
EA201792012A1 EA201792012A EA201792012A EA201792012A1 EA 201792012 A1 EA201792012 A1 EA 201792012A1 EA 201792012 A EA201792012 A EA 201792012A EA 201792012 A EA201792012 A EA 201792012A EA 201792012 A1 EA201792012 A1 EA 201792012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
impurities
removal
solutions during
during chromatography
interest
Prior art date
Application number
EA201792012A
Other languages
English (en)
Other versions
EA035635B1 (ru
Inventor
Цзюэ Ван
Нил Е. Джаффе
Крина Патель
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201792012A1 publication Critical patent/EA201792012A1/ru
Publication of EA035635B1 publication Critical patent/EA035635B1/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/50—Conditioning of the sorbent material or stationary liquid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

В некоторых вариантах осуществления в изобретении предлагается способ выделения представляющего интерес белка из смеси, которая содержит представляющий интерес белок и одно или несколько загрязняющих веществ, при этом указанный способ включает: a) подвергание смеси воздействию первой матрицы для хроматографии, при этом представляющий интерес белок связывается с первой матрицей для хроматографии; b) приведение в контакт первой матрицы для хроматографии с первым промывочным раствором, который имеет рН по меньшей мере 9,0 и не содержит аргинин или производное аргинина; и c) элюирование представляющего интерес белка с первой матрицы для хроматографии в элюционный раствор.
EA201792012A 2015-03-13 2016-03-11 Использование щелочных промывочных растворов во время хроматографии для удаления примесей EA035635B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132974P 2015-03-13 2015-03-13
PCT/US2016/021984 WO2016149088A1 (en) 2015-03-13 2016-03-11 Use of alkaline washes during chromatography to remove impurities

Publications (2)

Publication Number Publication Date
EA201792012A1 true EA201792012A1 (ru) 2018-01-31
EA035635B1 EA035635B1 (ru) 2020-07-17

Family

ID=55699796

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792012A EA035635B1 (ru) 2015-03-13 2016-03-11 Использование щелочных промывочных растворов во время хроматографии для удаления примесей

Country Status (13)

Country Link
US (2) US10695693B2 (ru)
EP (2) EP3268100A1 (ru)
JP (1) JP6807859B2 (ru)
KR (1) KR102490956B1 (ru)
CN (1) CN107636005B (ru)
AU (2) AU2016233557B2 (ru)
BR (1) BR112017018365A2 (ru)
CA (1) CA2978095C (ru)
EA (1) EA035635B1 (ru)
IL (1) IL254372B (ru)
MX (1) MX395730B (ru)
SG (2) SG11201707330RA (ru)
WO (1) WO2016149088A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073401A1 (en) * 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
KR102490956B1 (ko) 2015-03-13 2023-01-19 브리스톨-마이어스 스큅 컴퍼니 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도
EP4403193A3 (en) 2017-01-30 2025-01-22 Regeneron Pharmaceuticals, Inc. Method for reducing bioburden in chromatography
CN112566930A (zh) * 2018-06-19 2021-03-26 百时美施贵宝公司 使用色谱纯化蛋白质的方法
MX2021001915A (es) * 2018-08-17 2021-05-31 Regeneron Pharma Metodo y sistema de cromatografia para determinar la cantidad y pureza de una proteina multimerica.
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
ES2962578T3 (es) * 2018-10-31 2024-03-19 Regeneron Pharma Método y sistema de identificación y cuantificación de una proteína
US20210380638A1 (en) * 2018-12-21 2021-12-09 WuXi Biologics Ireland Limited A method for improving aggregate removal by Protein A chromatography
CA3123052A1 (en) * 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
CN109870428A (zh) * 2019-01-21 2019-06-11 江苏华泰疫苗工程技术研究有限公司 一种基于表面等离子共振技术的抗体定量检测方法
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
EP4653865A3 (en) 2019-09-24 2026-02-18 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
KR20220079844A (ko) * 2019-10-14 2022-06-14 피어스 바이오테크놀로지, 인크 펩티드 정제 제제 및 방법
EP4126900A4 (en) * 2020-03-27 2024-05-29 Haemalogix Ltd Composition and method
AR123688A1 (es) * 2020-10-02 2023-01-04 Lilly Co Eli Métodos para reducir el contenido de proteínas de célula huésped en procesos de purificación de proteínas
WO2025178923A1 (en) * 2024-02-20 2025-08-28 Exelixis, Inc. Methods for protein purification

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
JPS63276494A (ja) * 1987-02-26 1988-11-14 ダナーファーバー・キャンサー・インスチチュート・インコーポレーテッド Ｌｆａ−３の精製法
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
MD1367C2 (ru) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Методы лечения лимфомы В-клеток, антитела анти-CD20, гибридома.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
PT1308456E (pt) * 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US7763706B1 (en) * 2003-07-17 2010-07-27 Campina B.V. Arginine/lysine-enriched peptides
EP2336172B1 (en) * 2003-10-27 2014-12-10 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography
WO2006113959A2 (en) * 2005-04-26 2006-11-02 Sandoz Ag Production of recombinant proteins by autoproteolytic cleavage of a fusion protein
WO2007109163A2 (en) * 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
DK2061803T4 (da) * 2006-08-28 2022-12-05 Ares Trading Sa Fremgangsmåde til oprensning af fc-holdige proteiner
WO2008031020A2 (en) 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
CN101889025B (zh) * 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
AU2009347206C1 (en) * 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
EP2513134B1 (en) 2009-12-18 2017-09-06 Novartis AG Wash solution and method for affinity chromatography
JP2012001462A (ja) * 2010-06-15 2012-01-05 Kaneka Corp 抗体精製用カラム
BR112013030628B1 (pt) * 2011-06-01 2022-01-25 Novartis Ag Método para produção de uma proteína purificada de interesse utilizando uma matriz de cromatografia de afinidade, e método para produção de um anticorpo purificado, fragmento de anticorpo ou proteína de fusão de fc utilizando uma coluna de proteína a
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
KR102490956B1 (ko) 2015-03-13 2023-01-19 브리스톨-마이어스 스큅 컴퍼니 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도

Also Published As

Publication number Publication date
CN107636005B (zh) 2021-07-16
JP6807859B2 (ja) 2021-01-06
KR20170125948A (ko) 2017-11-15
KR102490956B1 (ko) 2023-01-19
BR112017018365A2 (pt) 2018-04-10
JP2018510867A (ja) 2018-04-19
US10695693B2 (en) 2020-06-30
MX2017011121A (es) 2017-11-28
EP3268100A1 (en) 2018-01-17
EP4194071A1 (en) 2023-06-14
US20180078876A1 (en) 2018-03-22
MX395730B (es) 2025-03-25
AU2016233557B2 (en) 2021-06-24
IL254372A0 (en) 2017-11-30
US12157073B2 (en) 2024-12-03
CN107636005A (zh) 2018-01-26
AU2021221870A1 (en) 2021-09-23
WO2016149088A1 (en) 2016-09-22
SG10201908027QA (en) 2019-10-30
IL254372B (en) 2022-05-01
US20200282332A1 (en) 2020-09-10
CA2978095A1 (en) 2016-09-22
AU2016233557A1 (en) 2017-11-02
CA2978095C (en) 2022-02-15
SG11201707330RA (en) 2017-10-30
EA035635B1 (ru) 2020-07-17

Similar Documents

Publication Publication Date Title
EA201792012A1 (ru) Использование щелочных промывочных растворов во время хроматографии для удаления примесей
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
PH12018500513A1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
SG10201900661YA (en) Purification platform for bispecific antibodies
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
MX388164B (es) Anticuerpos y fragmentos anti-vista
SG194460A1 (en) Wash solution and method for affinity chromatography
MX392628B (es) Amortiguador de lavado de cromatografia de afinidad.
JO3692B1 (ar) عوامل، استخدامات وطرق لعلاج مرض تنكسي عصبي
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2015195453A3 (en) Methods for increasing the capacity of flow-through processes
EP4389757A3 (en) Methods for purifying antibodies
MX389110B (es) Un metodo y un aparato para formar una fraccion de lignina, una composicion de lignina y su uso.
BR112019002979A2 (pt) método de cromatografia para quantificação de um tensoativo não iônico em uma composição compreen-dendo o tensoativo não iônico e um polipeptídeo
EA201791914A1 (ru) Способ селективного извлечения элементов халькофильной группы
EA201891469A1 (ru) Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний
AR117418A1 (es) Métodos para la purificación de polipéptidos usando polisorbatos
AR104358A1 (es) Método para la purificación de proteínas
MX2019001971A (es) Metodos y usos de fracciones de material organico disuelto para el enlace de iones metalicos.
EA201891990A1 (ru) Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
EA201691834A1 (ru) Новый способ очистки гонадотропина
EA201990052A1 (ru) ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Ха
BR112017013256A2 (pt) método de análise, portador de amostra em forma de disco e aplicação de um portador de amostra
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM